Vicarious Surgical (NYSE:RBOT – Get Free Report) is expected to announce its Q2 2026 resultson Thursday, July 30th. Analysts expect Vicarious Surgical to post earnings of ($1.15) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:30 PM ET.
Vicarious Surgical Stock Performance
Shares of NYSE:RBOT opened at $0.14 on Thursday. Vicarious Surgical has a 52-week low of $0.12 and a 52-week high of $13.75. The firm has a fifty day moving average of $0.44 and a 200 day moving average of $1.08. The firm has a market capitalization of $997,360.00, a PE ratio of -0.02 and a beta of 1.88.
Hedge Funds Weigh In On Vicarious Surgical
A number of hedge funds and other institutional investors have recently modified their holdings of the company. XTX Topco Ltd bought a new position in shares of Vicarious Surgical during the 4th quarter valued at about $27,000. Geode Capital Management LLC lifted its position in Vicarious Surgical by 26.0% in the 4th quarter. Geode Capital Management LLC now owns 40,494 shares of the company’s stock worth $88,000 after buying an additional 8,344 shares during the last quarter. Jane Street Group LLC bought a new stake in Vicarious Surgical in the 4th quarter worth approximately $98,000. Dimensional Fund Advisors LP boosted its stake in Vicarious Surgical by 22.1% in the third quarter. Dimensional Fund Advisors LP now owns 19,975 shares of the company’s stock worth $110,000 after buying an additional 3,615 shares in the last quarter. Finally, Connective Capital Management LLC purchased a new stake in Vicarious Surgical in the third quarter worth approximately $169,000. 47.27% of the stock is currently owned by hedge funds and other institutional investors.
About Vicarious Surgical
Vicarious Surgical develops a next-generation robotic surgical system that integrates virtual reality (VR) with minimally invasive instrumentation. Its flagship offering combines ultra-slender, articulated robotic arms with a VR surgeon console, allowing physicians to perform laparoscopic procedures with enhanced precision, dexterity and visual immersion. The platform is designed to reduce patient trauma compared with traditional open or laparoscopic surgery and to expand surgeon access to challenging operative sites.
The company’s technology is intended for use across multiple surgical specialties, including general surgery, gynecology and urology.
Recommended Stories
- Five stocks we like better than Vicarious Surgical
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Vicarious Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicarious Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
